Balaji Prasad
Stock Analyst at Barclays
(3.07)
# 1,218
Out of 4,905 analysts
132
Total ratings
44.35%
Success rate
0.02%
Average return
Main Sectors:
Stocks Rated by Balaji Prasad
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EOLS Evolus | Maintains: Overweight | $22 → $25 | $9.34 | +167.67% | 8 | Mar 5, 2025 | |
| AMRX Amneal Pharmaceuticals | Maintains: Overweight | $10 → $11 | $8.25 | +33.41% | 5 | Mar 3, 2025 | |
| PCRX Pacira BioSciences | Maintains: Overweight | $17 → $24 | $22.28 | +7.72% | 9 | Feb 28, 2025 | |
| VTRS Viatris | Maintains: Underweight | $12 → $9 | $9.27 | -2.91% | 8 | Feb 28, 2025 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Overweight | $190 → $200 | $114.86 | +74.13% | 10 | Feb 27, 2025 | |
| ELAN Elanco Animal Health | Maintains: Overweight | $20 → $19 | $14.96 | +27.01% | 13 | Feb 26, 2025 | |
| TARS Tarsus Pharmaceuticals | Maintains: Overweight | $62 → $60 | $41.43 | +44.82% | 5 | Feb 26, 2025 | |
| ZTS Zoetis | Maintains: Overweight | $242 → $244 | $150.03 | +62.63% | 16 | Feb 14, 2025 | |
| OGN Organon & Co. | Maintains: Overweight | $26 → $24 | $9.64 | +148.96% | 2 | Feb 14, 2025 | |
| PAHC Phibro Animal Health | Maintains: Underweight | $20 → $22 | $29.73 | -26.00% | 8 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $481 → $520 | $518.71 | +0.25% | 9 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $26 | $16.31 | +59.41% | 12 | Jan 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $17 → $17 | $14.69 | +15.72% | 13 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $22 → $18 | $8.73 | +106.19% | 5 | Jul 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $2.5 → $10 | $3.80 | +163.16% | 2 | Oct 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8 → $7 | $0.90 | +681.42% | 7 | Oct 23, 2023 |
Evolus
Mar 5, 2025
Maintains: Overweight
Price Target: $22 → $25
Current: $9.34
Upside: +167.67%
Amneal Pharmaceuticals
Mar 3, 2025
Maintains: Overweight
Price Target: $10 → $11
Current: $8.25
Upside: +33.41%
Pacira BioSciences
Feb 28, 2025
Maintains: Overweight
Price Target: $17 → $24
Current: $22.28
Upside: +7.72%
Viatris
Feb 28, 2025
Maintains: Underweight
Price Target: $12 → $9
Current: $9.27
Upside: -2.91%
Jazz Pharmaceuticals
Feb 27, 2025
Maintains: Overweight
Price Target: $190 → $200
Current: $114.86
Upside: +74.13%
Elanco Animal Health
Feb 26, 2025
Maintains: Overweight
Price Target: $20 → $19
Current: $14.96
Upside: +27.01%
Tarsus Pharmaceuticals
Feb 26, 2025
Maintains: Overweight
Price Target: $62 → $60
Current: $41.43
Upside: +44.82%
Zoetis
Feb 14, 2025
Maintains: Overweight
Price Target: $242 → $244
Current: $150.03
Upside: +62.63%
Organon & Co.
Feb 14, 2025
Maintains: Overweight
Price Target: $26 → $24
Current: $9.64
Upside: +148.96%
Phibro Animal Health
Feb 10, 2025
Maintains: Underweight
Price Target: $20 → $22
Current: $29.73
Upside: -26.00%
Feb 4, 2025
Maintains: Overweight
Price Target: $481 → $520
Current: $518.71
Upside: +0.25%
Jan 30, 2025
Maintains: Overweight
Price Target: $28 → $26
Current: $16.31
Upside: +59.41%
Nov 6, 2024
Maintains: Overweight
Price Target: $17 → $17
Current: $14.69
Upside: +15.72%
Jul 25, 2024
Maintains: Overweight
Price Target: $22 → $18
Current: $8.73
Upside: +106.19%
Oct 23, 2023
Maintains: Equal-Weight
Price Target: $2.5 → $10
Current: $3.80
Upside: +163.16%
Oct 23, 2023
Maintains: Overweight
Price Target: $8 → $7
Current: $0.90
Upside: +681.42%